Event
24th Schrödinger European User Group Meeting
Date: 19-21 May 2026
Location: Munich, Germany
Federico Munafò,
Senior Scientist, Medicinal Chemistry
Meet Axxam at the 24th Schrödinger European User Group Meeting
Axxam will attend the 24th Schrödinger European User Group Meeting, bringing together scientists and innovators working across computational chemistry, molecular modeling, drug discovery, and AI-driven research.
Representing Axxam at the event will be Federico Munafò, Senior Scientist, Medicinal Chemistry, who will join discussions around the evolving role of computational approaches in accelerating early drug discovery and supporting informed decision-making across hit identification and lead optimization.
Supporting Drug Discovery through Integrated Scientific Expertise
Early drug discovery increasingly depends on the integration of computational and experimental workflows. From virtual screening and molecular modeling to biochemical and cellular validation, combining in silico insights with robust laboratory data is becoming essential to improve efficiency and reduce risk in discovery programs.
Axxam medicinal chemistry activities are integrated within broader discovery strategies that connect:
- target biology
- assay development
- screening platforms
- hit identification
- hit-to-lead support
- compound management and profiling
This multidisciplinary approach helps translate scientific hypotheses into actionable discovery programs across multiple therapeutic areas.
Discover our AXXVirtual
The AXXVirtual Library is a curated collection of more than 185 million highly annotated, non-commercially available compounds designed to support efficient and scalable early drug discovery programs.
The library has been developed according to:
- physico-chemical property filters
- universal drug-likeness criteria
- synthetic feasibility principles
Compounds are designed to be rapidly synthesized using reliable and well-established chemical reactions starting from readily accessible building blocks. This approach enables faster exploration of chemical space and supports rapid follow-up around identified hits.
Key advantages include:
- access to a large and diverse virtual chemical space
- rapid hit expansion and SAR exploration
- customizable screening sets tailored to project needs
- support for structure-based and AI-enabled discovery workflows
- efficient integration with medicinal chemistry and screening strategies
By combining computational design approaches with experimental validation expertise, Axxam supports integrated discovery workflows aimed at accelerating hit identification and optimization.
Let’s connect during the event
If you are attending the 24th Schrödinger European User Group Meeting, connect with Federico to discuss how integrated discovery approaches can support your research programs and scientific objectives.
Whether your focus is computational chemistry, assay development, medicinal chemistry, or early discovery strategy, we look forward to exchanging ideas with the scientific community.
About Axxam
Axxam is a Contract Research Organization (CRO) supporting early drug discovery through integrated assay development, screening, compound management, and advanced in vitro platforms.